Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach

Donald A. Berry and Chih-Hsiang Ho
Biometrics
Vol. 44, No. 1 (Mar., 1988), pp. 219-227
DOI: 10.2307/2531909
Stable URL: http://www.jstor.org/stable/2531909
Page Count: 9
  • Read Online (Free)
  • Download ($14.00)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
One-Sided Sequential Stopping Boundaries for Clinical Trials: A Decision- Theoretic Approach
Preview not available

Abstract

We address one-sided stopping rules for clinical trials, or more generally, drug development programs, from a decision-theoretic point of view. If efficacy results are sufficiently negative then the trial will be stopped. But regardless of how positive the efficacy results are, the trial will continue in order to demonstrate safety. We show how sequential decisions should be made by a pharmaceutical company attempting to maximize its expected profits.

Page Thumbnails

  • Thumbnail: Page 
219
    219
  • Thumbnail: Page 
220
    220
  • Thumbnail: Page 
221
    221
  • Thumbnail: Page 
222
    222
  • Thumbnail: Page 
223
    223
  • Thumbnail: Page 
224
    224
  • Thumbnail: Page 
225
    225
  • Thumbnail: Page 
226
    226
  • Thumbnail: Page 
227
    227